Hello guys ,just saying hello ,really like this site seems to be low on bullshitters and good adviceto boot.i dont know if its cool on a1st post but why is anavar so hard to come by ,i can get everything else locally apart from that ,im in Newcastle uk we have tons of coal and 2 shit football teams if anyone fancies a swap ,cushty .
MESO-Rx
Anabolic Steroids
neil or no neil
- Thread starter ukneil
- Start date
Welcome man. If you're looking for someone to hit you up with a decent source you'll have to spend some time getting to know the place. Yeah guess you've always had coal, but no one blames you for the shit football teams 
dper726
Member
Football??? ah yes you mean soccer
Welcome to the board brother [
)]
Welcome to the board brother [
)]
Lol soccer, what the fuck is that?? op was referring to the game you use your feet for, the world game 
Even if local sources were selling anavar, there's a good chance it's really Winstrol or something else. You can search WEDINOS to see what others in you're area are getting: WEDINOS - Substance Information
juice_86
New Member
Here is what I came across
link:
Essentialdrugs.org
article:
One Example of Extreme Price Gouging:
The story of little orphan Oxandrolone
Oxandrolone is one effective treatment for HIV-related wasting, a
leading killer of people with more advanced AIDS. Oxandrolone has been
available by prescription for over 30 years and though it potentially
could have prevent countless deaths from HIV-associated wasting, it is
still rarely used for people with AIDS.
Oxandrolone is now being developed and marketed to people with
HIV-related wasting, but at a wholesale price more that 1,200% higher
than the price for which it was sold just 7 years ago. The story of how
the drug's developer, BTG, used the U.S. Orphan Drug Act to increase the
cost of oxandrolone more than 11-fold, is an example of everything that
is wrong with AIDS-drug pricing in the U.S.
Oxandrolone was by the FDA in the early 1960's at a dosage of 5-10 mg
per day for conditions which included weight loss "due to extensive
surgery, chronic infection, severe trauma, failure to gain or maintain
weight without definite pathophysiologic reasons [and] protein
catabolism due to prolonged corticosteroid administration." The drug has
been on the market long enough for all patents on it to expire and
therefore it should be available as a generic. Until 1989, the drug was
sold and manufactured by Searle Laboratories under the trade name Anavar
and by SPA Labs in Europe under the names Lipidex, Antitriol, or
Lonavar. The drug was used illegally by some bodybuilders to increase
muscular definition and was favored it for its low toxicity and few side
effects. It's black market price was reported at $3.00 per tablet. Its
regular pharmaceutical price as a generic was $0.30 per tablet.
The drug was discontinued by Searle Laboratories in 1989, partly because of
bad publicity due to its illegal use by bodybuilders. The drug was picked
up for marketing by New Jersey-based Bio-Technology General Corp (BTG), who
negotiated an arrangement where Searle would continue to manufacture the
drug and supply it to BTG. In a press release dated Dec.
5, 1995, Bio-Technology General Corp. announced "its first major U.S.
drug launch: Oxandrin(R) oxandrolone." The press release did not mention
oxadrolone's thirty year history as a treatment for wasting. It did state,
however, that "The recommended adult dose of Oxandrin(R) is 2.5 mg to 20 mg
per day. At an average wholesale price of $3.75 per 2.5 mg tablet,
Oxandrin(R) is a cost effective therapy for involuntary weight loss." This
announced average wholesale price was more that 12 times higher that the
wholesale price of oxandrolone in 1989, for exactly the same pills,
manufactured by exactly the same company, in exactly the same factory.
BTG's press release also explained that "AIDS wasting indications have
been granted Orphan Drug designation by the FDA. This designation is
granted to drugs for rare diseases or conditions with a prevalence of
less than 200,000 cases in the United States and provides the
manufacturer with seven years of market exclusivity post approval.." At
first look, this seems a grotesque misuse of the Orphan Drug designation to
make a formally inexpensively available generic drug, MORE THAN TWELVE
TIMES MORE EXPENSIVE.
At the previously FDA-approved dose of 10 mg per day, oxandrolone will
cost patients $15 per day or $5,475 per year. At higher doses of 40 or
80 mg per day, the annual cost would be or $21,900 or $43,800
respectively. Normally, consumers have the ability to obtain older
prescription as generic equivalents. However, by exploiting orphan drug
laws designed to help patients, BTG is attempting to monopolize the
market for oxandrolone and thereby charge monopolist prices. This price
is an unacceptable and exploitative mark-up of what should be an
inexpensive drug.
BTG has responded to concerns expressed by PWAs over the cost of
oxandrolone with a commitment to never charge any one patient more than
$15,000 per year for the drug, even if a doctor prescribes a higher
does. BTG also has committed to making Oxandrin available to people who
cannot afford it with a patient assistance program. However, many PWAs
report that their doctors are reluctant to prescribe Oxandrin because of
its high cost when compared to other injectable anabolic steroids, and
instead prescribe other therapies for wasting that are available as
generics and that cost much less. For these PWAs, oxandrolone is not a
treatment option, and they must use other drugs that may not work as well
and are harder to take.
--
James Love / Director, Consumer Project on Technology
CPTech Homepage / love@cptech.org
P.O. Box 19367, Washington, DC 20036
voice 202.387.8030 / fax 202.234.5176
link:
Essentialdrugs.org
article:
One Example of Extreme Price Gouging:
The story of little orphan Oxandrolone
Oxandrolone is one effective treatment for HIV-related wasting, a
leading killer of people with more advanced AIDS. Oxandrolone has been
available by prescription for over 30 years and though it potentially
could have prevent countless deaths from HIV-associated wasting, it is
still rarely used for people with AIDS.
Oxandrolone is now being developed and marketed to people with
HIV-related wasting, but at a wholesale price more that 1,200% higher
than the price for which it was sold just 7 years ago. The story of how
the drug's developer, BTG, used the U.S. Orphan Drug Act to increase the
cost of oxandrolone more than 11-fold, is an example of everything that
is wrong with AIDS-drug pricing in the U.S.
Oxandrolone was by the FDA in the early 1960's at a dosage of 5-10 mg
per day for conditions which included weight loss "due to extensive
surgery, chronic infection, severe trauma, failure to gain or maintain
weight without definite pathophysiologic reasons [and] protein
catabolism due to prolonged corticosteroid administration." The drug has
been on the market long enough for all patents on it to expire and
therefore it should be available as a generic. Until 1989, the drug was
sold and manufactured by Searle Laboratories under the trade name Anavar
and by SPA Labs in Europe under the names Lipidex, Antitriol, or
Lonavar. The drug was used illegally by some bodybuilders to increase
muscular definition and was favored it for its low toxicity and few side
effects. It's black market price was reported at $3.00 per tablet. Its
regular pharmaceutical price as a generic was $0.30 per tablet.
The drug was discontinued by Searle Laboratories in 1989, partly because of
bad publicity due to its illegal use by bodybuilders. The drug was picked
up for marketing by New Jersey-based Bio-Technology General Corp (BTG), who
negotiated an arrangement where Searle would continue to manufacture the
drug and supply it to BTG. In a press release dated Dec.
5, 1995, Bio-Technology General Corp. announced "its first major U.S.
drug launch: Oxandrin(R) oxandrolone." The press release did not mention
oxadrolone's thirty year history as a treatment for wasting. It did state,
however, that "The recommended adult dose of Oxandrin(R) is 2.5 mg to 20 mg
per day. At an average wholesale price of $3.75 per 2.5 mg tablet,
Oxandrin(R) is a cost effective therapy for involuntary weight loss." This
announced average wholesale price was more that 12 times higher that the
wholesale price of oxandrolone in 1989, for exactly the same pills,
manufactured by exactly the same company, in exactly the same factory.
BTG's press release also explained that "AIDS wasting indications have
been granted Orphan Drug designation by the FDA. This designation is
granted to drugs for rare diseases or conditions with a prevalence of
less than 200,000 cases in the United States and provides the
manufacturer with seven years of market exclusivity post approval.." At
first look, this seems a grotesque misuse of the Orphan Drug designation to
make a formally inexpensively available generic drug, MORE THAN TWELVE
TIMES MORE EXPENSIVE.
At the previously FDA-approved dose of 10 mg per day, oxandrolone will
cost patients $15 per day or $5,475 per year. At higher doses of 40 or
80 mg per day, the annual cost would be or $21,900 or $43,800
respectively. Normally, consumers have the ability to obtain older
prescription as generic equivalents. However, by exploiting orphan drug
laws designed to help patients, BTG is attempting to monopolize the
market for oxandrolone and thereby charge monopolist prices. This price
is an unacceptable and exploitative mark-up of what should be an
inexpensive drug.
BTG has responded to concerns expressed by PWAs over the cost of
oxandrolone with a commitment to never charge any one patient more than
$15,000 per year for the drug, even if a doctor prescribes a higher
does. BTG also has committed to making Oxandrin available to people who
cannot afford it with a patient assistance program. However, many PWAs
report that their doctors are reluctant to prescribe Oxandrin because of
its high cost when compared to other injectable anabolic steroids, and
instead prescribe other therapies for wasting that are available as
generics and that cost much less. For these PWAs, oxandrolone is not a
treatment option, and they must use other drugs that may not work as well
and are harder to take.
--
James Love / Director, Consumer Project on Technology
CPTech Homepage / love@cptech.org
P.O. Box 19367, Washington, DC 20036
voice 202.387.8030 / fax 202.234.5176
GS44
New Member
Because VAR costs more and sources try to put cheaper powders so they can rip you off as well give them more money.
Welcome.
Similar threads
